Clinical trial · Observational
Radiogenomic and Prognosis Analysis in Glioma
Prospective Observational Study of Imaging-based Prediction for Genomic Mutations and Prognosis in Glioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate whether MRI can be used to predict genomics and prognosis in glioma. Given the profound prognostic significance of genetic mutations seen in glioma, there have been increasing attempts to correlate imaging characteristics with genetic, mutational and expression patterns. To be able to predict genomics and prognosis based on imaging alone will prove useful in patients with involvement of glioma in delicate areas of the brain and better reflect tumor and molecular heterogeneity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Glioma
- description
- Patients suspected of glioma
- interventionNames
- Diagnostic Test: MRI
Primary outcomes (1)
- measure
- Time to progression
- timeFrame
- Through study completion, an average of 2 years
- description
- The response was determined by a modification of the response assessment in neuro-oncology (RANO) criteria that combined the image assessment, neurologic evaluation and assessment of steroid use.
Secondary outcomes (2)
- measure
- Genomics including IDH mutation, 1p19q codeletion, MGMT methylation and EGFR mutation status
- timeFrame
- 2 months
- description
- Proportion of positive IDH mutation, 1p19q codeletion, MGMT methylation and EGFR mutation in percentage (%)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients suspected of glioma undergoing MRI examination prior to surgery * MRI including advanced imaging such as cerebral blood volume, apparent diffusion coefficient and amide proton transfer imaging * Signed informed consent Exclusion Criteria: * Pathologic confirmation as tumors other than glioma * Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulates, electronic infusion pumps, etc), because such devices may be displaced or malfunction * Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential
References
Publications (0)
Data not yet available